PainReform (PRFX) Competitors

$1.45 0.00 (0.00%)

As of 12:55 PM Eastern

PRFX vs. DCOY, CASI, CANF, HCWB, and ELAB

Should you buy PainReform stock or one of its competitors? MarketBeat compares PainReform with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with PainReform include Decoy Therapeutics (DCOY), CASI Pharmaceuticals (CASI), Can-Fite BioPharma (CANF), HCW Biologics (HCWB), and PMGC (ELAB). These companies are all part of the "pharmaceutical products" industry.

How does PainReform compare to Decoy Therapeutics?

PainReform (NASDAQ:PRFX) and Decoy Therapeutics (NASDAQ:DCOY) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, valuation, profitability, earnings, dividends and risk.

Decoy Therapeutics has a consensus price target of $30.00, indicating a potential upside of 349.78%. Given Decoy Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Decoy Therapeutics is more favorable than PainReform.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PainReform	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Decoy Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

PainReform's return on equity of 0.00% beat Decoy Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PainReform	N/A	N/A	N/A
Decoy Therapeutics	N/A	-395.42%	-193.30%

PainReform has a beta of 0.77, suggesting that its stock price is 23% less volatile than the broader market. Comparatively, Decoy Therapeutics has a beta of 0.38, suggesting that its stock price is 62% less volatile than the broader market.

PainReform has higher revenue and earnings than Decoy Therapeutics. Decoy Therapeutics is trading at a lower price-to-earnings ratio than PainReform, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PainReform	$20K	29.00	-$5.02M	-$736.66	N/A
Decoy Therapeutics	N/A	N/A	-$12.52M	-$106.90	N/A

In the previous week, Decoy Therapeutics had 2 more articles in the media than PainReform. MarketBeat recorded 2 mentions for Decoy Therapeutics and 0 mentions for PainReform. PainReform's average media sentiment score of 0.00 equaled Decoy Therapeutics'average media sentiment score.

Company	Overall Sentiment
PainReform	Neutral
Decoy Therapeutics	Neutral

37.3% of PainReform shares are owned by institutional investors. Comparatively, 11.9% of Decoy Therapeutics shares are owned by institutional investors. 34.4% of PainReform shares are owned by insiders. Comparatively, 0.3% of Decoy Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

PainReform beats Decoy Therapeutics on 8 of the 13 factors compared between the two stocks.

How does PainReform compare to CASI Pharmaceuticals?

PainReform (NASDAQ:PRFX) and CASI Pharmaceuticals (NASDAQ:CASI) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, valuation, earnings, profitability, analyst recommendations, dividends, institutional ownership and media sentiment.

PainReform has a beta of 0.77, meaning that its stock price is 23% less volatile than the broader market. Comparatively, CASI Pharmaceuticals has a beta of 0.91, meaning that its stock price is 9% less volatile than the broader market.

37.3% of PainReform shares are owned by institutional investors. Comparatively, 22.2% of CASI Pharmaceuticals shares are owned by institutional investors. 34.4% of PainReform shares are owned by insiders. Comparatively, 21.2% of CASI Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

PainReform has a net margin of 0.00% compared to CASI Pharmaceuticals' net margin of -183.93%.

Company	Net Margins	Return on Equity	Return on Assets
PainReform	N/A	N/A	N/A
CASI Pharmaceuticals	-183.93%	N/A	-131.54%

PainReform has higher earnings, but lower revenue than CASI Pharmaceuticals. CASI Pharmaceuticals is trading at a lower price-to-earnings ratio than PainReform, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PainReform	$20K	29.00	-$5.02M	-$736.66	N/A
CASI Pharmaceuticals	$26.85M	0.10	-$39.26M	-$3.01	N/A

In the previous week, CASI Pharmaceuticals had 1 more articles in the media than PainReform. MarketBeat recorded 1 mentions for CASI Pharmaceuticals and 0 mentions for PainReform. PainReform's average media sentiment score of 0.00 equaled CASI Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
PainReform	Neutral
CASI Pharmaceuticals	Neutral

CASI Pharmaceuticals has a consensus price target of $4.00, indicating a potential upside of 1,827.71%. Given CASI Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe CASI Pharmaceuticals is more favorable than PainReform.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PainReform	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
CASI Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

PainReform and CASI Pharmaceuticals tied by winning 7 of the 14 factors compared between the two stocks.

How does PainReform compare to Can-Fite BioPharma?

Can-Fite BioPharma (NYSE:CANF) and PainReform (NASDAQ:PRFX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, risk, analyst recommendations, profitability, media sentiment, dividends, earnings and valuation.

Can-Fite BioPharma currently has a consensus price target of $42.50, indicating a potential upside of 1,137.26%. Given Can-Fite BioPharma's stronger consensus rating and higher possible upside, research analysts clearly believe Can-Fite BioPharma is more favorable than PainReform.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Can-Fite BioPharma	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
PainReform	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

PainReform has lower revenue, but higher earnings than Can-Fite BioPharma. Can-Fite BioPharma is trading at a lower price-to-earnings ratio than PainReform, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Can-Fite BioPharma	$405K	5.56	-$7.63M	-$35.80	N/A
PainReform	$20K	29.00	-$5.02M	-$736.66	N/A

Can-Fite BioPharma has a beta of 1.09, meaning that its share price is 9% more volatile than the broader market. Comparatively, PainReform has a beta of 0.77, meaning that its share price is 23% less volatile than the broader market.

Company	Net Margins	Return on Equity	Return on Assets
Can-Fite BioPharma	N/A	N/A	N/A
PainReform	N/A	N/A	N/A

21.0% of Can-Fite BioPharma shares are owned by institutional investors. Comparatively, 37.3% of PainReform shares are owned by institutional investors. 0.8% of Can-Fite BioPharma shares are owned by insiders. Comparatively, 34.4% of PainReform shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Can-Fite BioPharma had 3 more articles in the media than PainReform. MarketBeat recorded 3 mentions for Can-Fite BioPharma and 0 mentions for PainReform. Can-Fite BioPharma's average media sentiment score of 0.67 beat PainReform's score of 0.00 indicating that Can-Fite BioPharma is being referred to more favorably in the media.

Company	Overall Sentiment
Can-Fite BioPharma	Positive
PainReform	Neutral

Summary

Can-Fite BioPharma beats PainReform on 8 of the 13 factors compared between the two stocks.

How does PainReform compare to HCW Biologics?

PainReform (NASDAQ:PRFX) and HCW Biologics (NASDAQ:HCWB) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, valuation, profitability, media sentiment and institutional ownership.

PainReform has higher earnings, but lower revenue than HCW Biologics. HCW Biologics is trading at a lower price-to-earnings ratio than PainReform, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PainReform	$20K	29.00	-$5.02M	-$736.66	N/A
HCW Biologics	$6.59M	3.16	-$7.96M	-$9.46	N/A

PainReform has a net margin of 0.00% compared to HCW Biologics' net margin of -34.73%. PainReform's return on equity of 0.00% beat HCW Biologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PainReform	N/A	N/A	N/A
HCW Biologics	-34.73%	-486.87%	-29.19%

PainReform has a beta of 0.77, suggesting that its share price is 23% less volatile than the broader market. Comparatively, HCW Biologics has a beta of 1.13, suggesting that its share price is 13% more volatile than the broader market.

37.3% of PainReform shares are held by institutional investors. Comparatively, 3.0% of HCW Biologics shares are held by institutional investors. 34.4% of PainReform shares are held by company insiders. Comparatively, 9.1% of HCW Biologics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, HCW Biologics had 12 more articles in the media than PainReform. MarketBeat recorded 12 mentions for HCW Biologics and 0 mentions for PainReform. HCW Biologics' average media sentiment score of 0.19 beat PainReform's score of 0.00 indicating that HCW Biologics is being referred to more favorably in the news media.

Company	Overall Sentiment
PainReform	Neutral
HCW Biologics	Neutral

HCW Biologics has a consensus price target of $35.00, indicating a potential upside of 1,031.59%. Given HCW Biologics' stronger consensus rating and higher probable upside, analysts clearly believe HCW Biologics is more favorable than PainReform.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PainReform	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
HCW Biologics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

PainReform and HCW Biologics tied by winning 8 of the 16 factors compared between the two stocks.

How does PainReform compare to PMGC?

PMGC (NASDAQ:ELAB) and PainReform (NASDAQ:PRFX) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, valuation, media sentiment, analyst recommendations, dividends and profitability.

In the previous week, PMGC had 2 more articles in the media than PainReform. MarketBeat recorded 2 mentions for PMGC and 0 mentions for PainReform. PMGC's average media sentiment score of 0.42 beat PainReform's score of 0.00 indicating that PMGC is being referred to more favorably in the media.

Company	Overall Sentiment
PMGC	Neutral
PainReform	Neutral

22.2% of PMGC shares are held by institutional investors. Comparatively, 37.3% of PainReform shares are held by institutional investors. 0.0% of PMGC shares are held by company insiders. Comparatively, 34.4% of PainReform shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

PainReform's return on equity of 0.00% beat PMGC's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PMGC	N/A	-117.82%	-70.79%
PainReform	N/A	N/A	N/A

PMGC has a beta of -0.27, meaning that its stock price is 127% less volatile than the broader market. Comparatively, PainReform has a beta of 0.77, meaning that its stock price is 23% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PMGC	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
PainReform	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

PainReform has lower revenue, but higher earnings than PMGC. PMGC is trading at a lower price-to-earnings ratio than PainReform, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PMGC	$1.27M	1.56	-$7.75M	-$168.62	N/A
PainReform	$20K	29.00	-$5.02M	-$736.66	N/A

Summary

PainReform beats PMGC on 8 of the 12 factors compared between the two stocks.

Get PainReform News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PRFX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PRFX vs. The Competition

Export

Metric	PainReform	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$584K	$3.02B	$6.38B	$12.35B
Dividend Yield	N/A	1.96%	2.79%	5.33%
P/E Ratio	0.00	17.76	20.90	25.65
Price / Sales	29.00	299.74	547.42	85.21
Price / Cash	N/A	57.57	44.13	56.16
Price / Book	0.06	4.59	10.09	7.06
Net Income	-$5.02M	$74.99M	$3.55B	$335.04M
7 Day Performance	-8.23%	0.14%	4.61%	2.53%
1 Month Performance	-41.77%	-4.87%	1.36%	1.37%
1 Year Performance	-85.13%	35.45%	36.73%	35.63%

PainReform Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PRFX PainReform	0.7272 of 5 stars	$1.45 flat	N/A	-84.5%	$584K	$20K	N/A	4	Gap Down
DCOY Decoy Therapeutics	2.2339 of 5 stars	$4.82 -6.4%	$30.00 +522.4%	N/A	$2.56M	N/A	N/A	20	Gap Up
CASI CASI Pharmaceuticals	1.2038 of 5 stars	$0.21 flat	$4.00 +1,827.7%	N/A	$2.55M	$26.85M	N/A	180
CANF Can-Fite BioPharma	2.8829 of 5 stars	$3.64 +7.4%	$42.50 +1,067.6%	-83.4%	$2.38M	$405K	N/A	8	Gap Up
HCWB HCW Biologics	1.7329 of 5 stars	$0.35 +2.9%	$35.00 +9,917.2%	-70.3%	$2.35M	$50K	N/A	40	News Coverage Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PRFX) was last updated on 5/22/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

PainReform (PRFX) Competitors

PRFX vs. DCOY, CASI, CANF, HCWB, and ELAB

How does PainReform compare to Decoy Therapeutics?

Summary

How does PainReform compare to CASI Pharmaceuticals?

Summary

How does PainReform compare to Can-Fite BioPharma?

Summary

How does PainReform compare to HCW Biologics?

Summary

How does PainReform compare to PMGC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRFX vs. The Competition

PainReform Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

PainReform (PRFX) Competitors

PRFX vs. DCOY, CASI, CANF, HCWB, and ELAB

How does PainReform compare to Decoy Therapeutics?

Do analysts prefer PRFX or DCOY?

Is PRFX or DCOY more profitable?

Which has more risk & volatility, PRFX or DCOY?

Which has preferable valuation and earnings, PRFX or DCOY?

Does the media prefer PRFX or DCOY?

Do institutionals & insiders believe in PRFX or DCOY?

Summary

How does PainReform compare to CASI Pharmaceuticals?

Which has more volatility and risk, PRFX or CASI?

Do institutionals and insiders have more ownership in PRFX or CASI?

Is PRFX or CASI more profitable?

Which has higher earnings and valuation, PRFX or CASI?

Does the media prefer PRFX or CASI?

Do analysts recommend PRFX or CASI?

Summary

How does PainReform compare to Can-Fite BioPharma?

Do analysts prefer CANF or PRFX?

Which has better earnings & valuation, CANF or PRFX?

Which has more volatility and risk, CANF or PRFX?

Is CANF or PRFX more profitable?

Do institutionals & insiders believe in CANF or PRFX?

Does the media favor CANF or PRFX?

Summary

How does PainReform compare to HCW Biologics?

Which has stronger valuation & earnings, PRFX or HCWB?

Is PRFX or HCWB more profitable?

Which has more volatility and risk, PRFX or HCWB?

Do insiders and institutionals have more ownership in PRFX or HCWB?

Does the media refer more to PRFX or HCWB?

Do analysts recommend PRFX or HCWB?

Summary

How does PainReform compare to PMGC?

Does the media favor ELAB or PRFX?

Do institutionals & insiders believe in ELAB or PRFX?

Is ELAB or PRFX more profitable?

Which has more volatility and risk, ELAB or PRFX?

Do analysts rate ELAB or PRFX?

Which has better valuation & earnings, ELAB or PRFX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRFX vs. The Competition

PainReform Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools